BioCeuticals UltraBiotic 500 (7 sachets)

BioCeuticals UltraBiotic 500 (7 sachets).png
BioCeuticals UltraBiotic 500 (7 sachets) - supplement facts.JPG
BioCeuticals UltraBiotic 500 (7 sachets).png
BioCeuticals UltraBiotic 500 (7 sachets) - supplement facts.JPG

BioCeuticals UltraBiotic 500 (7 sachets)

0.00

UltraBiotic 500 is a combination of 14 probiotic strains providing 500 billion CFU per 5g sachet. This high strength probiotic provides support for normal healthy digestive and immune systems in a convenient one-a-day dose. It provides good bacteria which may help maintain intestinal flora when taken during and after antibiotic therapy.

Halal and Kosher certified.

Add To Cart

Intestinal microbiota
The microflora of the digestive tract is diverse, consisting of a synergistic mileu of different bacteria, all of which contribute to the health and balance of the intestinal environment.
With over 400 microbial species inhabiting our gut,[1] species of lactobacillus and bifidobacterium are prominent members of the normal flora of the gastrointestinal tract (GIT),[2,3] and the probiotic strains in UltraBiotic 500 are commonly found in the GIT.
Probiotics also cooperate to maintain the relationship between the GIT and the immune system. A healthy intestinal tract has appropriate bacterial colonisation that prevents overgrowth of unhealthy bacteria.
UltraBiotic 500 has been formulated to be taken during and after antibiotic therapy to recolonise the normal intestinal microflora that may be disrupted when taking antibiotics.

UB500.jpg

Probiotics during and after antibiotic therapy

Background: Disturbance of the microbiota is frequently associated with diarrhoea, gastritis, glossitis and pruritus as well as fungal infections.
Subjects/Method: 155 patients infected with Helicobacter pylori in this double-blind, placebo-controlled trial received antibiotics (standard eradication therapy: amoxicillin 1g, clarithromycin 500mg and lansoprazole 30mg, twice daily) from days 1-7. The active group (n=76) received probiotics (Lactobacillus acidophilus CUL 60 + CUL 21 and two strains of Bifidobacterium spp.) from days 1-21, while the control group (n=79) received placebo.
Results: Despite the probiotic supplement, the microbiota of both the control and active groups were susceptible to the effects of the administered antibiotics. However, supplementation with probiotics resulted in less disruption of the compositional balance in the active group compared with the control group. Daily supplementation with viable probiotic bacteria during and after antibiotic therapy reduces the extent of disruption to the intestinal microbiota as well as the incidence and total numbers of antibiotic-resistant strains in the regrowth population.

Plummer SF, Garaiova I, Sarvotham T, et al. Effects of probiotics on the composition of the intestinal microbiota following antibiotic therapy. Int J Antimicrob Agents 2005;26(1):69-74.

    • Mild, temporary gastrointestinal disturbances, such as increased flatulence, may occur with amounts exceeding one billion live organisms. If this occurs reduce the dose, then gradually increase it over time.
    • It is recommended to take probiotics at least four hours away from antibiotics to limit a potential reduction in probiotic effectiveness.[5]

    [1] Gerritsen J, Smidt H, Rijkers GT,et al. Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr 2011;6(3):209-240.

    [2] Walter J. Ecological role of lactobacilli in the gastrointestinal tract: implications for fundamental and biomedical research. Appl Environ Microbiol 2008;74(16):4985-4996.

    [3] Salminen S, Wright A (eds). Lactic acid bacteria: microbiology and functional aspects. 2nd edition. New York: Marcel Dekker, 1998.

    [4] Jakobssen HE, Jernberg C, Andersson AF, et al. Short-term antibiotic treatment has differing impacts on the human throat and gut microbiome. PLoS One 2010;5(3):e9836.

    [5] Hawrelak JA. Probiotics. In: Pizzorno JE, Murray MT (Eds), Textbook of natural medicine, 3rd ed (pp.1195-1215). St Louis: Churchill Livingstone Elsevier, 2006.